[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202192738A1 - Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos - Google Patents

Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos

Info

Publication number
EA202192738A1
EA202192738A1 EA202192738A EA202192738A EA202192738A1 EA 202192738 A1 EA202192738 A1 EA 202192738A1 EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A1 EA202192738 A1 EA 202192738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
aiolos
ikaros
tricyclic compounds
compounds providing
Prior art date
Application number
EA202192738A
Other languages
English (en)
Inventor
Джэймс А. Хендерсон
Миньшэн Хэ
Эндрю Чарльз Гуд
Эндрю Дж. Филиппс
Original Assignee
С4 Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by С4 Терапьютикс, Инк. filed Critical С4 Терапьютикс, Инк.
Publication of EA202192738A1 publication Critical patent/EA202192738A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Описаны трициклические связывающие цереблон молекулы для разрушения белка Ikaros или белка Aiolos посредством убиквитин-протеасомного пути для терапевтических применений.
EA202192738A 2019-04-12 2020-04-10 Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos EA202192738A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833107P 2019-04-12 2019-04-12
PCT/US2020/027678 WO2020210630A1 (en) 2019-04-12 2020-04-10 Tricyclic degraders of ikaros and aiolos

Publications (1)

Publication Number Publication Date
EA202192738A1 true EA202192738A1 (ru) 2022-03-17

Family

ID=72750851

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192738A EA202192738A1 (ru) 2019-04-12 2020-04-10 Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos

Country Status (14)

Country Link
US (2) US11407732B1 (ru)
EP (1) EP3953332A4 (ru)
JP (1) JP2022527216A (ru)
KR (1) KR20210152515A (ru)
CN (1) CN113677664A (ru)
AU (1) AU2020272978A1 (ru)
BR (1) BR112021019669A2 (ru)
CA (1) CA3130469A1 (ru)
EA (1) EA202192738A1 (ru)
IL (1) IL287116A (ru)
MA (1) MA55628A (ru)
MX (1) MX2021012524A (ru)
SG (1) SG11202109024YA (ru)
WO (1) WO2020210630A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
JP7323603B2 (ja) * 2018-09-07 2023-08-08 メッドシャイン ディスカバリー インコーポレイテッド 三環式縮合フラン置換ピペリジンジオン系化合物
BR112022011827A2 (pt) 2019-12-20 2022-08-30 C4 Therapeutics Inc Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
TW202146412A (zh) 2020-03-05 2021-12-16 美商Ｃ４醫藥公司 用於標靶降解brd9之化合物
EP4192450A4 (en) * 2020-08-07 2024-08-21 C4 Therapeutics Inc BENEFICIAL THERAPIES FOR IKAROS OR AIOLOS MEDIATED DISORDERS
CA3194343A1 (en) * 2020-10-14 2022-04-21 Christopher G. Nasveschuk Tricyclic heterobifunctional compounds for degradation of targeted proteins
EP4228639A1 (en) * 2020-10-14 2023-08-23 C4 Therapeutics, Inc. Tricyclic ligands for degradation of ikzf2 or ikzf4
KR20240017814A (ko) 2021-05-05 2024-02-08 바이오젠 엠에이 인코포레이티드 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
JP2024525580A (ja) 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
EP4367113A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
AU2022335547A1 (en) * 2021-08-27 2024-04-04 Hangzhou Glubio Pharmaceutical Co. Ltd. Isoindolinone compound and use thereof
WO2023059792A1 (en) * 2021-10-06 2023-04-13 C4 Thrapeutics, Inc. Coronavirus non-structural protein 3 degrading compounds
CN118201923A (zh) * 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
KR20240146048A (ko) * 2022-02-09 2024-10-07 씨4 테라퓨틱스, 인코포레이티드 Cft7455의 형태학적 형태 및 그의 제조 방법
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116120261B (zh) * 2022-11-30 2024-01-23 浙大宁波理工学院 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法
WO2024193641A1 (zh) * 2023-03-21 2024-09-26 上海超阳药业有限公司 异吲哚啉衍生物和苯并吲哚衍生物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ575061A (en) 2006-08-30 2011-10-28 Celgene Corp 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
SI2066656T1 (sl) 2006-09-26 2012-06-29 Celgene Corp Zamenjani derivati kinazolinona kot protitumorska sredstva
ES2601131T3 (es) 2007-03-20 2017-02-14 Celgene Corporation Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos
MX347987B (es) 2007-09-26 2017-05-22 Celgene Corp * Derivados de quinazolinona 6-,7-, u 8-sustituidos y composiciones que los comprenden y metodos para usar los mismos.
WO2009139880A1 (en) 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
BRPI0919942B1 (pt) 2008-10-29 2019-02-19 Celgene Corporation Composto, composição farmacêutica que o compreende e uso do referido composto
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
CA3206268A1 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
AU2017206382C1 (en) 2016-01-14 2020-12-24 Kangpu Biopharmaceuticals, Ltd Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
AU2017376704B2 (en) 2016-12-16 2021-08-05 Kangpu Biopharmaceuticals, Ltd. Composition, application thereof and treatment method
CA3053805C (en) 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
RU2728829C1 (ru) 2017-02-28 2020-07-31 Канпу Биофармасьютикалз, Лтд. Новое изоиндолиновое производное, включающая его фармацевтическая композиция и его применение
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019241274A1 (en) 2018-06-13 2019-12-19 Biotheryx, Inc. Aminoamide compounds
EP3813834A4 (en) 2018-06-29 2022-03-09 Dana Farber Cancer Institute, Inc. NEW CRBN MODULATORS
WO2020006265A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Bispecific degraders
JP7328263B2 (ja) 2018-06-29 2023-08-16 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫調節化合物
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN112261970A (zh) 2018-07-10 2021-01-22 诺华股份有限公司 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途
CA3151824A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
EP4077319A1 (en) 2019-12-20 2022-10-26 Calico Life Sciences LLC Protein tyrosine phosphatase degraders and methods of use thereof

Also Published As

Publication number Publication date
US11407732B1 (en) 2022-08-09
MX2021012524A (es) 2021-11-12
SG11202109024YA (en) 2021-09-29
EP3953332A4 (en) 2023-06-14
JP2022527216A (ja) 2022-05-31
US20230082430A1 (en) 2023-03-16
MA55628A (fr) 2022-02-16
KR20210152515A (ko) 2021-12-15
AU2020272978A1 (en) 2021-09-16
BR112021019669A2 (pt) 2021-12-07
IL287116A (en) 2021-12-01
WO2020210630A1 (en) 2020-10-15
EP3953332A1 (en) 2022-02-16
CA3130469A1 (en) 2020-10-15
CN113677664A (zh) 2021-11-19

Similar Documents

Publication Publication Date Title
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1123746T1 (el) Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer
EA201992546A1 (ru) Средства на основе антител к cd33
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA201790288A1 (ru) Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12020552229A1 (en) Il-11ra antibodies
JOP20200074A1 (ar) أجسام مضادة ضد tau واستخداماتها
EA200901313A1 (ru) Ингибиторы тирозинкиназы брутона
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
EA201992083A1 (ru) Модуляторы соматостатина и их применения
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
EA201991029A1 (ru) Ингибиторы magl
ATE437185T1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
BR112022000855A2 (pt) Moduladores de nlrp3
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
CY1126054T1 (el) Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων
EA202192488A1 (ru) Антитела против tsg-6 и их применения